Epitalon Has Been Studied in Russia for Over 40 Years. The FDA Still Doesn’t Trust the Data.

Epitalon Has Been Studied in Russia for Over 40 Years. The FDA Still Doesn’t Trust the Data.

Epitalon Has Been Studied in Russia for Over 40 Years. The FDA Still Doesn’t Trust the Data. Complete Guide to Peptides Editorial Team This article is provided for general informational purposes only and is not medical advice. Speak to a qualified healthcare professional before making any decisions about peptide use. Epitalon isn’t a new discovery…

KPV and the FDA: What the July 2026 Vote Covered

KPV and the FDA: What the July 2026 Vote Covered

KPV and the FDA: What the July 2026 Vote Covered Complete Guide to Peptides Editorial Team This article is provided for general informational purposes only and is not medical advice. Speak to a qualified healthcare professional before making any decisions about peptide use. KPV rounded out the trio of near-identical 8-6 votes on day one…

Melanotan II: The Tanning Peptide With More Going On Than the Name Suggests
|

Melanotan II: The Tanning Peptide With More Going On Than the Name Suggests

Melanotan II: The Tanning Peptide With More Going On Than the Name Suggests In the 1980s researchers at the University of Arizona had a hypothesis that seemed almost too elegant to be true. Skin cancer rates were rising. The primary cause was UV radiation from sun exposure. The body already had a natural mechanism for…

KPV — The Anti-Inflammatory Tripeptide That Works Without Suppressing Immunity
|

KPV — The Anti-Inflammatory Tripeptide That Works Without Suppressing Immunity

KPV — The Anti-Inflammatory Tripeptide That Works Without Suppressing Immunity Most anti-inflammatory compounds face an uncomfortable trade-off. Suppress the inflammatory pathways and you risk suppressing the immune function that those pathways support. Corticosteroids are the most obvious example effective at reducing inflammation but at the cost of immune suppression, skin thinning and systemic effects that…

End of content

End of content